Posters
Intraocular pressure reduction following iStent inject�Â�® implantation in primary open-angle glaucoma eyes depending on lens condition and further previous surgery
Poster Details
First Author: F.Ruefer GERMANY
Co Author(s): M. Matth�Ã�¤i J. F�Ã�¶rster T. Herbst D. Holland
Abstract Details
Purpose:
To compare the IOP-lowering effect after iStent inject�Â�® Implantation in eyes with POAG with different lens conditions and after previous surgery.
Setting:
Single center single surgeon study
Methods:
83 eyes of 56 patients with POAG aged 41�â��95 years (mean 67�Â�±12 years) were included. The IOP was measured preoperatively and postoperatively after 1 day, 1 week, and 1,3, and 6 months after iStent inject�Â�® implantation. IOP development and the number of antiglaucomatous drugs were recorded for phakic eyes which underwent stand alone procedure (PhSTA; n=8), phakic eyes with combinated cataract surgery (PhKOM; n=51), pseudophakic eyes without further previous surgery (PsPh; n=16), and pseudophakic eyes with previous surgery with conjunctiva involvement (PsPh; n=8). The last group included 6 eyes after trabeculectomy and 2 eyes after pars plana vitrectomy.
Results:
The mean IOP (mmHg) of the collective group was 6 months postoperatively (preoperative values in brackets) 15.2�Â�±2.9 (19.1�Â�±4.3) and in subgroups PhSTA 18.5�Â�±2.8 (20.8�Â�±3.1), PhKOM 14.6�Â�±1.9 (19.4�Â�±4.3), PsPh 15.8�Â�±2.0 (17.1�Â�±3.5), and PsPh 14.9�Â�±5.6 (20.0�Â�±5.2). In the collective group, the mean number of the given topical antiglaucomatous agents was 6 months after stent implantation (preoperative in brackets) 1.2 (2.0) and in subgroups PhSTA 1.1 (1.4), PhKOM 0.8 (1.8) PsPh 1.7 (2.4), and PsPh 1.8 (2.4).
Conclusions:
In eyes with POAG the IOP-lowering effect after iStent inject�Â�® implantation can be observed in eyes with combinated cataract surgery, in eyes after stand alone procedure, in pseudophakic eyes as well as in pseudophakic eyes with previous trabeculectomy or pars plana vitrectomy. In all groups, the need for topical antiglaucomatous agents could be reduced. These results imply a wide range of indications for the procedure.
Financial Disclosure:
NONE
